Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
医学
贫血
透析
重症监护医学
内科学
作者
Glenn M. Chertow,Pablo E. Pérgola,Youssef M.K. Farag,Rajiv Agarwal,Susan Arnold,Gabriel Bako,Geoffrey A. Block,Steven K. Burke,Fausto P. Castillo,Alan G. Jardine,Zeeshan Khawaja,Mark J. Koury,Eldrin F. Lewis,Tim Lin,Wei Luo,Bradley J. Maroni,Kunihiro Matsushita,Peter A. McCullough,Patrick S. Parfrey,Prabir Roy‐Chaudhury
Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO2TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).